• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Greenwich LifeSciences Inc.

    6/22/22 11:53:43 AM ET
    $GLSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLSI alert in real time by email
    SC 13G 1 formsc13g.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2(b)

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. )*

     

    Greenwich LifeSciences, Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    396879108

    (CUSIP Number)

     

    December 29, 2021

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the Rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d – 1(b)
      ☒ Rule 13d – 1(c)
      ☐ Rule 13d – 1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Michael Weiner

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    USA

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

     
    6.

    SHARED VOTING POWER

    2,304,681

     
    7.

    SOLE DISPOSITIVE POWER

     

     
    8.

    SHARED DISPOSITIVE POWER

    2,304,681

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,304,681

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    17.7% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -2-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Yosajo MA Trust 1

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    105,662

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    105,662

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    105,662

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.8% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -3-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Yosajo MA Trust 2

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    105,632

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    105,632

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    105,632

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.8% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -4-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Yosajo MA Trust 3

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    94,812

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    94,812

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    94,812

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.7% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -5-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Yosajo MI Trust 1

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    94,763

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    94,763

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    94,763

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.7% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -6-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Yosajo MI Trust 2

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    94,751

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    94,751

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    94,751

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.7% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -7-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    Yosajo MI Trust 3

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    105,554

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    105,554

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    105,554

         
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
         
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.8% (1)

         
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -8-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    WLUFMI Trust 1

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    421,841

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    421,841

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    421,841

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.2% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -9-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    WLUFMI Trust 2

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    424,816

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    424,816

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    424,816

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.3% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -10-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    WLUFMA Trust 1

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    429,692

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    429,692

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    429,692

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.3% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -11-

     

     

    CUSIP No. 396879108
      1.

    NAME OF REPORTING PERSON OR

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

    WLUFMA Trust 2

     
      2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
         
        (a) ☒
        (b) ☐
     
      3.

    SEC USE ONLY

     

     
      4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    TX

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

    427,158

     
    6.

    SHARED VOTING POWER

     

     
    7.

    SOLE DISPOSITIVE POWER

    427,158

     
    8.

    SHARED DISPOSITIVE POWER

     

     

      9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    427,158

     
      10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
     
      11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.3% (1)

     
      12.

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    OO

     

    (1) Based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -12-

     

     

    Item 1(a). Name of Issuer:
       
      Greenwich LifeSciences, Inc., a Delaware corporation (the “Issuer”)
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      3992 Bluebonnet Dr., Building 14, Stafford, Texas 77477
       
    Item 2(a). Name of Person Filing.
       
     

    This statement is filed on behalf of Michael Weiner, an individual (the “Reporting Person”).

     

    Mr. Weiner is the trustee for the Yosajo MA Trust 1, Yosajo MA Trust 2, Yosajo MA Trust 3, Yosajo MI Trust 1, Yosajo MI Trust 2, Yosajo MI Trust 3, WLUFMI Trust 1, WLUFMI Trust 2, WLUFMA Trust 1 and WLUFMA Trust 2.

       
    Item 2(b). Address of Principal Business Office or, if None, Residence.
       
      The address for the Reporting Person is:
       
     

    Westport, CT 06880

       
    Item 2(c). Citizenship.
       
      USA
       
    Item 2(d). Title of Class of Securities.
       
      Common Stock
       
    Item 2(e). CUSIP Number.
       
      396879108
       
    Item 3. Type of Person.
       
      Not applicable.
       
    Item 4. Ownership.
       
     

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each of the Reporting Persons hereto, including footnotes, and is incorporated herein by reference for the Reporting Persons. The percentage set forth in Row (11) of the cover page for each of the Reporting Persons are calculated based on 13,000,357 shares of common stock disclosed by the Issuer as outstanding as of May 19, 2022, as reported on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on May 20, 2022.

     

    -13-

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      Not applicable.
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      Not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company.
       
      Not applicable.
       
    Item 8. Identification and Classification of Members of the Group.
       
      Not applicable.
       
    Item 9. Notice of Dissolution of Group.
       
      Not applicable.
       
    Item 10. Certifications.
       
      Not applicable

     

    -14-

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: June 22, 2022 Michael Weiner
      /s/ Michael Weiner

     

    -15-

     

    Get the next $GLSI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GLSI

    DatePrice TargetRatingAnalyst
    9/1/2021$78.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $GLSI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Greenwich LifeSciences Inc.

      10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

      5/20/25 4:30:30 PM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Greenwich LifeSciences Inc.

      NT 10-Q - Greenwich LifeSciences, Inc. (0001799788) (Filer)

      5/15/25 4:15:32 PM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Greenwich LifeSciences Inc.

      10-K - Greenwich LifeSciences, Inc. (0001799788) (Filer)

      4/15/25 4:30:24 PM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and CFO Patel Snehal bought $35,568 worth of shares (3,600 units at $9.88), increasing direct ownership by 0.06% to 5,570,602 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/29/25 6:14:15 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and CFO Patel Snehal bought $48,492 worth of shares (5,400 units at $8.98), increasing direct ownership by 0.10% to 5,567,002 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/22/25 6:05:03 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and CFO Patel Snehal bought $32,760 worth of shares (3,600 units at $9.10), increasing direct ownership by 0.06% to 5,561,602 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/8/25 6:05:08 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on Greenwich LifeSciences with a new price target

      HC Wainwright & Co. initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $78.00

      9/1/21 6:15:30 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital initiated coverage on Greenwich LifeSciences with a new price target

      Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00

      1/27/21 6:00:07 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital initiated coverage on Greenwich LifeSciences with a new price target

      Aegis Capital initiated coverage of Greenwich LifeSciences with a rating of Buy and set a new price target of $75.00

      1/26/21 10:33:29 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and CFO Patel Snehal bought $35,568 worth of shares (3,600 units at $9.88), increasing direct ownership by 0.06% to 5,570,602 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/29/25 6:14:15 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and CFO Patel Snehal bought $48,492 worth of shares (5,400 units at $8.98), increasing direct ownership by 0.10% to 5,567,002 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/22/25 6:05:03 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and CFO Patel Snehal bought $32,760 worth of shares (3,600 units at $9.10), increasing direct ownership by 0.06% to 5,561,602 units (SEC Form 4)

      4 - Greenwich LifeSciences, Inc. (0001799788) (Issuer)

      4/8/25 6:05:08 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Greenwich LifeSciences Provides Global Update on FLAMINGO-01

      STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following global update on FLAMINGO-01. Flamingo-01 Progress to Date & Future Plans The Company recently confirmed that the preliminary HLA prevalence, safety, and immune response data in FLAMINGO-01 patients is trending as expected in both HLA-A*02 and non-HLA-A*02 arms. The non-HLA-A*02 arm was expanded to 250 patients in 2024 with approval from both EU and US regulators. With t

      4/3/25 8:00:00 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

      STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label immune response data. FLAMINGO-01 Immune Response Data Summary The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types (non- HLA-A*02), show that GLSI-100 is creating an immune response over tim

      4/2/25 6:00:00 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

      STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to March 31, 2026 which is approximately 66 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modif

      3/27/25 6:00:00 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Greenwich LifeSciences Inc.

      SC 13G - Greenwich LifeSciences, Inc. (0001799788) (Subject)

      6/22/22 11:53:43 AM ET
      $GLSI
      Biotechnology: Pharmaceutical Preparations
      Health Care